News for 'Sun Pharmaceutical Industries'

10 Stocks That May Gain From Budget

10 Stocks That May Gain From Budget

Rediff.com4 Feb 2026

The fiscal tilt towards capex benefits companies in investment-related sectors like capital goods, defence equipment, engineering & construction and metal & mining. The planned cut in revenue expenditure will weigh on companies in consumption sectors like FMCG, consumer durables and retail.

India, New Zealand conclude FTA negotiations

India, New Zealand conclude FTA negotiations

Rediff.com22 Dec 2025

New Zealand Prime Minister Christopher Luxon on Monday said the negotiations for a free trade agreement with India have been concluded.

India Inc holds breath for Trump's new tariffs to kick in

India Inc holds breath for Trump's new tariffs to kick in

Rediff.com27 Feb 2025

Industry insiders in India warn that any such move in the pharmaceutical sector could be counterproductive for the US as it may face increased drug shortages if tariffs are imposed on such imports.

Trump announces 100% tariffs on foreign-made movies, India to be hit

Trump announces 100% tariffs on foreign-made movies, India to be hit

Rediff.com30 Sep 2025

Trump said California has been particularly "hard hit" because of this, blaming democrat Gavin Newsom, the Governor of California, for this loss, calling him "weak and incompetent."

Sensex down 275 points on fag-end selling

Sensex down 275 points on fag-end selling

Rediff.com10 Dec 2025

Among the Sensex constituents, Eternal, Trent, Bharti Airtel, Infosys, Tech Mahindra, UltraTech Cement, ICICI Bank, HDFC Bank, Bajaj Finance, Tata Consultancy Services, Bharat Electronics Ltd, Larsen & Toubro and Tata Motors Passenger Vehicles were the laggards. However, Tata Steel, Sun Pharmaceuticals, ITC, NTPC, Reliance Industries, HCL Technologies, PowerGrid, and Asian Paints were among the gainers.

Sensex jumps 427 points on buying in metal, auto shares

Sensex jumps 427 points on buying in metal, auto shares

Rediff.com11 Dec 2025

Among the Sensex constituents, Eternal, Tata Steel, Kotak Mahindra Bank, UltraTech Cement, Maruti Suzuki India, Sun Pharmaceuticals, Tech Mahindra, HDFC Bank, Tata Motors Passenger Vehicles, Infosys, Trent, Mahindra & Mahindra, Reliance Industries and HCL Technologies were the gainers. However, Asian Paints, Bharti Airtel, Bajaj Finance, PowerGrid, Axis Bank, ICICI Bank and Titan were among the laggards.

Sensex, Nifty tank nearly 1% on selling in pharma, IT shares

Sensex, Nifty tank nearly 1% on selling in pharma, IT shares

Rediff.com26 Sep 2025

Most pharma shares dropped, dragging the BSE Healthcare index down by 2.14 per cent after Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1. Wockhardt shares tanked 9.4 per cent.

India, Oman to ink free trade agreement during PM Narendra Modi visit

India, Oman to ink free trade agreement during PM Narendra Modi visit

Rediff.com13 Dec 2025

Next week's three-nation foreign tour of Prime Minister Narendra Modi will see India and Oman sign a free trade deal. The visit will also pave the way for agreements with Ethiopia and Jordan to increase India's bilateral trade and investments.

Union Budget 2026: Sitharaman tries to cover all bases, leaves out markets

Union Budget 2026: Sitharaman tries to cover all bases, leaves out markets

Rediff.com1 Feb 2026

Budget 2026 sticks to fiscal discipline, shuns populist measures despite five key state elections coming up, but ends up rattling stock markets with a higher transaction tax on derivatives trading.

Budget 2023: What the pharma, healthcare industry seek

Budget 2023: What the pharma, healthcare industry seek

Rediff.com19 Jan 2023

The government should take measures to promote innovation and R&D while simplifying regulations for the sector in the upcoming Union Budget, as per pharmaceutical industry bodies. Outlining the wish list for the sector in the upcoming Union Budget, Indian Pharmaceutical Alliance (IPA) secretary general Sudarshan Jain said the domestic pharma industry is currently around $50 billion in size and aspires to grow to around $130 billion by 2030 and $450 billion by 2047. "To achieve this vision, the Union Budget 2023-2024 should help fuel innovation and R&D, which will set the pace for propelling the pharmaceutical industry forward," he told PTI.

Rupee Fall: Who Stands To Gain?

Rupee Fall: Who Stands To Gain?

Rediff.com25 Nov 2025

So far this year, the rupee has fallen by 4.2 per cent, the worst among its Asian peers.

What Putin hopes to achieve on his India visit

What Putin hopes to achieve on his India visit

Rediff.com3 Dec 2025

Russian President Vladimir Putin's visit to India this week aims to secure energy supplies, stabilise defence deliveries and ensure bilateral trade continues smoothly despite strong Western sanctions, GTRI said on Tuesday.

'India Should Not Rush To Celebrate Trump's Trade Announcement'

'India Should Not Rush To Celebrate Trump's Trade Announcement'

Rediff.com3 Feb 2026

'Trump says India will buy over $500 billion of US goods.' 'At present, India's annual imports of goods and energy from the US are under $50 billion.' 'Reaching $500 billion would likely require more than 20 years, suggesting the figure refers to a long-term aspiration rather than a near-term commitment.'

Sensex, Nifty settle with modest gains

Sensex, Nifty settle with modest gains

Rediff.com14 Nov 2025

From the Sensex pack, Eternal, Bharat Electronics Ltd, Trent, Axis Bank, State Bank of India, Bajaj Finance, Sun Pharmaceuticals, Asian Paints, Adani Ports, Hindustan Unilever, Reliance Industries, ITC, PowerGrid, Tata Motors Ltd's Commercial Vehicles business, and Bajaj Finserv were the gainers. Infosys, Tata Motors Passenger Vehicles, Tata Steel, ICICI Bank, Tech Mahindra, Titan, UltraTech Cement, Maruti Suzuki India, and Larsen & Toubro were the laggards.

What Weapons Will Putin Sell India On Rare State Visit?

What Weapons Will Putin Sell India On Rare State Visit?

Rediff.com29 Nov 2025

On the table are additional batches of S-400 surface-to-air missile systems from Russia, which India used with immense success during Operation Sindoor. India could buy at least two squadrons of Su-57 fighter jets plus joint production of S-500 air defence systems.

India's Medtech Industry To Develop High-end Equipment

India's Medtech Industry To Develop High-end Equipment

Rediff.com17 Apr 2025

According to the Department of Pharmaceuticals' annual report for 2024-25, India imported medical devices worth $8.1 billion, while exports stood at $3.7 billion in the financial year 2023-24 (FY24)

Tylenol row may not hit India's pharma exports

Tylenol row may not hit India's pharma exports

Rediff.com29 Sep 2025

Amid controversy over USPresident Donald Trump's comments linking the use of Tylenol and other related paracetamol products by pregnant women to autism in children, experts and industry executives say that since India's export of the drug to the US is less, it will hardly affect the country's pharma exports to America.

Indian pharma eyes US gains as $63.7 bn patent cliff nears

Indian pharma eyes US gains as $63.7 bn patent cliff nears

Rediff.com30 Jun 2025

The Indian pharmaceutical industry is likely to benefit from a major wave of patent expiries in the US, as small-molecule drugs worth $63.7 billion are expected to go off-patent between 2025-29, a 65 per cent rise over the previous five years, according to a report by Antique stock broking limited.

Will Tata Sons Get RBI Relief?

Will Tata Sons Get RBI Relief?

Rediff.com24 Oct 2025

Tata Sons, now debt-free, has asked the RBI to drop its 'upper-layer NBFC' tag and allow it to stay private.

Sensex jumps 595 points on strong global cues

Sensex jumps 595 points on strong global cues

Rediff.com12 Nov 2025

From the Sensex pack, Asian Paints, Tech Mahindra, Tata Consultancy Services, Bajaj Finserv, Adani Ports, HCL Technologies, Bharti Airtel, Infosys, Trent, Reliance Industries, UltraTech Cement, Sun Pharmaceuticals, Eternal, Titan and Bajaj Finance were the gainers. On the other hand, Tata Steel, Tata Motors Passenger Vehicles, Tata Motors Commercial Vehicles, Bharat Electronics, Kotak Mahindra Bank and PowerGrid were the laggards.

USFDA's new draft biosimilar rules to benefit Indian biotech cos

USFDA's new draft biosimilar rules to benefit Indian biotech cos

Rediff.com9 Nov 2025

The US Food and Drug Administration's (USFDA)'s new draft guidelines aimed at speeding up and reducing the cost of developing biosimilars - lower-priced, near-replicas of complex biologic medicines - could significantly benefit Indian biotech companies.

This will Likely Shape the Future of Pharma Inc

This will Likely Shape the Future of Pharma Inc

Rediff.com8 Mar 2025

Indian pharmaceutical companies may have units abroad as part of "distributed manufacturing" across various locations, according to industry veterans. This may come about over the next five to 10 years.

Sun Pharmaceutical's vital signs: A strong dose of valuation multiples

Sun Pharmaceutical's vital signs: A strong dose of valuation multiples

Rediff.com13 Nov 2023

Bolstered by an impressive performance in the global specialty business and outstanding results in the Indian market, Sun Pharmaceutical Industries, the largest pharmaceutical (pharma) company in the country, showcased a strong performance in the July-September quarter (second quarter, or Q2) of 2023-24 (FY24).

Where The Deadly Cough Syrup Was Made

Where The Deadly Cough Syrup Was Made

Rediff.com18 Oct 2025

Sandwiched between a Hero MotoCorp showroom and a shop that hires out cooking utensils is a small, dingy building that's been locked up. The non-descript two-room building is a manufacturing unit of Sresan Pharmaceuticals, the pharma company made its Coldriff cough syrup that has allegedly killed 25 children in Madhya Pradesh.

Health care, pharma IPOs raise Rs 14,811 cr in 2024

Health care, pharma IPOs raise Rs 14,811 cr in 2024

Rediff.com23 Dec 2024

India's healthcare and pharmaceutical sectors raised Rs 14,811 crore through initial public offerings (IPOs) in 2024, the largest since 2019, driven by strong domestic demand amid expanding global opportunities. According to data, key contributors to the record fundraising included Sai Life Sciences (Rs 3,043 crore), IKS Health (Rs 2,498 crore), and Sagility India (Rs 2,107 crore).

'Indian Youth Can Expect Career Growth In Russia'

'Indian Youth Can Expect Career Growth In Russia'

Rediff.com4 Dec 2025

'Don't look at Russia only as a place to earn quickly and then leave.' 'Try to build experience in serious companies, skills and certifications that will serve you anywhere in the world.'

Mankind taps OpenAI to institutionalise AI in ops

Mankind taps OpenAI to institutionalise AI in ops

Rediff.com18 Sep 2025

Delhi-based pharma major Mankind Pharma on Wednesday announced a collaboration with OpenAI to institutionalise artificial intelligence (AI) across its value chain, making it one of the first few Indian pharmaceutical companies to fully integrate advanced AI into its core operations.

GST cut on drugs, medical devices to help patients

GST cut on drugs, medical devices to help patients

Rediff.com4 Sep 2025

The government's move to cut GST on medicines and medical devices while exempting lifesaving drugs from the levy is a bold step that will bring direct relief to patients and families while significantly reducing financial strain on them, pharmaceuticals and healthcare industry players said on Thursday.

Cough syrup deaths: No state follows pharma safety norms

Cough syrup deaths: No state follows pharma safety norms

Rediff.com10 Oct 2025

The Central Drugs Standard Control Organisation (CDSCO) will conduct testing, inspection and auditing of cough syrup manufacturers.

Indian Pharma Gets Relief from Trump's Tariffs

Indian Pharma Gets Relief from Trump's Tariffs

Rediff.com4 Apr 2025

Indian drugmakers supply 47 per cent of the generic medicine requirements in the US, and tariffs would have increased prices in the US domestic market for patients, who are already dealing with drug shortages.

Highest Selling New Drug In India Is...

Highest Selling New Drug In India Is...

Rediff.com11 Feb 2025

Enhertu currently costs around Rs 1.6 lakh per 100-milligram injection.

Factors that will guide the markets this week

Factors that will guide the markets this week

Rediff.com18 May 2025

Stock markets will be mainly driven by quarterly earnings by corporates, foreign fund flows and global trends this week, analysts said.

Generic industry unlikely to be affected by Trump's EO: Indian drug cos

Generic industry unlikely to be affected by Trump's EO: Indian drug cos

Rediff.com14 May 2025

A fresh US executive order (EO) which seeks to bring down prices of prescription drugs in the country by up to 90 per cent -- on par with other developed nations -- will affect innovator companies, while sparing the Indian generic drug makers in the short term. US President Donald Trump signed the EO on Monday, directing the US Trade Representative and the Secretary of Commerce to act against foreign countries that "purposefully and unfairly undercut market prices", driving price hikes in the US.

How India's pharma cos plan to tackle steep US tariffs

How India's pharma cos plan to tackle steep US tariffs

Rediff.com10 Sep 2025

As the potential threat of a steep 200 per cent tariff on pharmaceutical imports hangs in the air, analysts and industry insiders feel that focus on exports to non-US regions as well as domestic market will increase as a long-term trend. US President Donald Trump told CNBC's Squawk Box in the first week of August that planned tariffs on import of pharmaceutical products to the US could eventually reach up to 250 per cent.

Kremlin Didn't Know About Modi Gesture

Kremlin Didn't Know About Modi Gesture

Rediff.com5 Dec 2025

The Russians have termed Putin's visit to India, his first to this country since the outbreak of the Russia-Ukraine war, as 'Druzhba Dosti', which means 'friendship' in Russian and Hindi respectively.

Cough syrup deaths: IMA slams doctor's arrest

Cough syrup deaths: IMA slams doctor's arrest

Rediff.com7 Oct 2025

The Indian Medical Association (IMA) has defended a doctor arrested in connection with cough syrup deaths in Madhya Pradesh, attributing the incident to failures in the drugs regulatory system.

Govt Targets 100 Products For Aatmanirbhar Push

Govt Targets 100 Products For Aatmanirbhar Push

Rediff.com16 Sep 2025

'Our endeavour will be that we identify these products, put them in the public domain so that the manufacturers can look at them and give a boost to Make in India.'

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Rediff.com31 Jul 2025

India's pharmaceuticals and medical devices industries are still hopeful that trade negotiations with the US could cut a fairer deal for both sides, after President Donald Trump announced a 25 per cent tariff rate on India on a social networking platform without divulging the finer details.

Modi, Putin unveil 2030 roadmap amid US pressure

Modi, Putin unveil 2030 roadmap amid US pressure

Rediff.com5 Dec 2025

India and Russia have solidified a five-year plan to enhance their economic and trade partnership, while also addressing the ongoing conflict in Ukraine and the threat of terrorism.

Factors that will drive the markets this week

Factors that will drive the markets this week

Rediff.com28 Sep 2025

Stock markets will be driven by RBI's interest rate decision, tariff-related developments, global trends and trading activity of foreign investors in this holiday-shortened week, analysts said.